Two COVID-19 vaccines are currently being administered in the UK – nonetheless there are loads of more which were ordered and are but to be licensed.
The Pfizer-BioNTech jab bought the UK’s COVID-19 vaccine programme off to a delivery up on 8 December after being given emergency approval by the Medicines and Healthcare products Regulatory Agency (MHRA) now not up to a week before.
On 4 January, the Oxford-AstraZeneca jab additionally began being administered after approval on 30 December.
Handiest one other vaccine has been licensed since nonetheless the authorities has ordered 300 million doses of 5 other vaccines.
These are the ones which have but to be rolled out or licensed:
Accredited: Moderna – 17m doses ordered
The Moderna vaccine became licensed on 7 January and is anticipated to be rolled out in April when it is sent over from the US.
It’s far an mRNA vaccine, handle the Pfizer jab, and trials have stumbled on it to be 95% efficient in preventing COVID-19.
No longer licensed: Novavax – 60m doses ordered
The Novavax vaccine is looking ahead to approval from the MHRA, which is anticipated imminently nonetheless is already being manufactured in England.
Novavax, an American vaccine style firm that additionally has services in Sweden, began increasing a COVID vaccine in January 2020.
It’s far a protein subunit vaccine that contains the spike protein of the COVID virus.
In January 2021, its half three trials stumbled on it had 89.3% efficacy and equipped solid immunity in opposition to new variants, including the Kent one.
Its vaccine is being made at Fujifilm’s location in Billington, Stockton-on-Tees and will undergo its “dangle and develop” at a GlaxoSmithKline (GSK) facility in Barnard Castle, County Durham.
No longer licensed: Janssen (Johnson & Johnson) – 30m doses ordered
Handiest one jab is required of this viral vector vaccine – the identical form of know-how as AstraZeneca’s.
Please utilize Chrome browser for a more accessible video participant
It became licensed in the US in February and the EU in March after trials stumbled on it became 67% efficient at preventing COVID-19 and fully efficient at preventing clinical institution admissions and loss of life from the virus.
Janssen Prescribed pills is a Belgian subsidiary of pharma broad Johnson & Johnson, so the jab is being referred to by each and every names.
No longer licensed: Valneva – 100m doses ordered
The French pharmaceutical firm’s jab is peaceable in trials nonetheless manufacturing has begun at a location in West Lothian, Scotland.
It makes utilize of lazy total virus know-how – a ineffective model of the coronavirus that can’t reason disease nonetheless will have to peaceable yelp the physique’s immune gadget the arrangement to fight it.
If it is licensed, 60m doses are expected to be administered in the second half of of 2021 and the final 40m next twelve months in case boosters are wanted.
No longer licensed: GlaxoSmithKline/Sanofi Pasteur – 60m doses ordered
Trials had to belayed in December after half one and two results stumbled on a low immune response in adults over 49.
They were restarted in February with more volunteers, including older adults, and if the records is definite it will probably transfer to unhurried-stage trials in the second quarter of 2021.
The UK pills broad and its French accomplice, which is the greatest firm devoted completely to vaccines in the world, have stated a vaccine will be available by the final quarter of 2021.
Please utilize Chrome browser for a more accessible video participant
No longer licensed: CureVac – 50m doses ordered
An mRNA vaccine, handle Pfizer’s and Moderna’s, the German firm is in half three trials.
It’s far additionally working with the UK authorities and GSK to develop a new quantity of vaccine that could defend in opposition to more than one new COVID traces in a single jab.
After half one trials, the firm stated its first-generation vaccine carefully mimics the immune response after natural COVID-19 an infection.
A specialist in RNA know-how for the past 20 years, CureVac joined the UK Vaccines Taskforce in February.
CureVac’s take care of the UK involves being ready to develop its vaccines within the UK.
